Skip to main content

Valion Bio, Inc.

corporate_fare Company Profile

Valion Bio, Inc.

VBIO·NASDAQ·Life Sciences·CIK 0001787740

Tivic Health Systems, Inc. is a late-stage biopharmaceutical company focused on developing Entolimod, a recombinant TLR5 agonist. Entolimod is being developed as a medical countermeasure for Acute Radiation Syndrome (ARS) and its related conditions, and as an additional therapy for oncology indications like neutropenia. During fiscal year 2025, Tivic Health underwent a significant strategic change, shifting from a diversified bioelectronic medical device company to a biopharmaceutical company centered on its TLR5 agonist franchise. In February 2025, Tivic secured worldwide exclusive license rights and options for Entolimod and its second-generation compound, Entolasta. In December 2025, the company established Velocity Bioworks, a subsidiary contract development and manufacturing organization (CDMO) intended to support both Tivic and selected third-party clients. Concurrently, Tivic exited the consumer healthtech business and paused its prescription bioelectronic product development to fully dedicate resources to Entolimod. The company is now focused on two main areas: advancing Entolimod and Entolasta through regulatory approval for acute radiation syndrome and into government procurement, and expanding Entolimod's uses to include oncology-related conditions such as neutropenia, thrombocytopenia, and general and specific mucositis. Tivic's common stock trades on The Nasdaq Capital Market under the symbol "TIVC." The company is headquartered in San Antonio, TX, and operates a Current Good Manufacturing Practice (CGMP)-compatible biomanufacturing facility in San Antonio, Texas, through Velocity Bioworks. It uses a hybrid remote and on-site operational model.

Valion Bio, Inc. (NASDAQ:VBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for VBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for VBIO spans 8-K, S-3, DEF 14A, PRE 14A.

Recent high-impact activity:

  • Valion Bio Stockholders Grant Board 1-for-2 to 1-for-12 Reverse Split Authority
  • Valion Bio Loses President, COO and CFO Lisa Wolf in Single Resignation
  • Valion Bio Fires General Counsel; Entolimod Advances to Fully Funded AFRRI Efficacy Study
  • NIAID Advances Entolimod Into Fully Funded GI-ARS Efficacy Study; December Data Readout
  • Valion Bio Reports Clean Entolimod Safety Data, Advancing to Fully Funded AFRRI Efficacy Study

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$8.88M
Op. Cash Flow
-$7M
Free Cash Flow
-$7.04M
Operating Income
-$7.9M
Cash & Equivalents
$12.64M
Total Debt
$6.45M
Debt / Equity
0.38×
Shares Outstanding
2.53M sh
Source: 10-K · filed 2026-03-30 · accession 0001437749-26-010343

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 230,766 shares in VBIO as of the October 30, 2026 settlement, a 99.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 43.2% of VBIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)230,766 shares as of October 30, 2026
Change vs prior period▲ 99.8%
Days to cover1.00 at avg daily volume of 1,684,819
Daily short volume (FINRA facilities)43.2% of 88,025 shares on November 20, 2026
5-day average short volume47.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for VBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-10-08.

ATM program3 shelf registrationsreverse split

$100M Shelf Registration Filed · $5M ATM Program with Rodman & Renshaw

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with V →
$0.473 -1.58% today
52-week range · as of 2026-11-16 $0.4715 – $67.5
Market cap
$1.04M
Volume
137.7K (0.1× avg)
3-mo avg 1.2M
Live data · 2026-11-22 06:00 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VBIO - Latest Insights

VBIO
Nov 16, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.510
Real-time Price: $0.473 info
Change: -$0.037 (-7%) info
Market Cap: $1.036M info
VBIO
Nov 05, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.502
Real-time Price: $0.473 info
Change: -$0.029 (-6%) info
Market Cap: $1.036M info
VBIO
Nov 02, 2026, 7:50 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.585
Real-time Price: $0.473 info
Change: -$0.112 (-19%) info
Market Cap: $1.036M info
VBIO
Oct 30, 2026, 7:50 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.6373
Real-time Price: $0.473 info
Change: -$0.1643 (-26%) info
Market Cap: $1.036M info
VBIO
Oct 29, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6758
Real-time Price: $0.473 info
Change: -$0.2028 (-30%) info
Market Cap: $1.036M info
VBIO
Oct 27, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.765
Real-time Price: $0.473 info
Change: -$0.292 (-38%) info
Market Cap: $1.036M info
VBIO
Oct 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.920
Real-time Price: $0.473 info
Change: -$0.447 (-49%) info
Market Cap: $1.036M info
VBIO
Oct 26, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $0.473 info
Change: -$0.6785 (-59%) info
Market Cap: $1.036M info
VBIO
Oct 16, 2026, 5:25 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.13
Real-time Price: $0.473 info
Change: -$0.657 (-58%) info
Market Cap: $1.036M info
VBIO
Oct 16, 2026, 4:48 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $0.473 info
Change: -$0.677 (-59%) info
Market Cap: $1.036M info
VBIO
Oct 07, 2026, 8:14 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $0.473 info
Change: -$1.68 (-78%) info
Market Cap: $1.036M info
VBIO
Oct 05, 2026, 10:08 AM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $0.473 info
Change: -$1.93 (-80%) info
Market Cap: $1.036M info
VBIO
Sep 30, 2026, 7:45 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $0.473 info
Change: -$2.86 (-86%) info
Market Cap: $1.036M info
VBIO
Sep 23, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $0.473 info
Change: -$2.08 (-81%) info
Market Cap: $1.036M info
VBIO
Sep 01, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.26
Real-time Price: $0.473 info
Change: -$2.79 (-85%) info
Market Cap: $1.036M info
VBIO
Aug 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.13255
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Aug 24, 2026, 7:41 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.142
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Aug 19, 2026, 9:09 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.1299
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Aug 17, 2026, 6:04 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1716
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Aug 14, 2026, 7:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.1785
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets